GSK Consumer announces next big allergy switch for 2017

WARREN, N.J. - GSK Consumer Healthcare on Wednesday unveiled the next big switch that will hit allergy aisles in 2017 - the U.S. Food and Drug Administration approved the company's Flonase Sensimist Allergy Relief (fluticasone furoate, 27.5 mcg spray) as an over-the-counter treatment for symptoms associated with seasonal and perennial allergies.

Previously available by prescription as Veramyst, Flonase Sensimist is the latest Rx-to-OTC switch from GSK.

"There are roughly 50 million people in the United States who suffer from allergies, and, as a category leader, GSK continues to innovate to satisfy the needs of all allergy sufferers," stated Amardeep Kahlon, director of marketing, GSK Consumer. "In the case of Flonase Sensimist, GSK is proud to offer an additional treatment option that not only provides more complete allergy symptom relief but also suits specific consumer preferences."

Flonase Sensimist helps block six allergic substances, providing non-drowsy, 24-hour relief of both nose- and eye-related allergy symptoms like itchy, watery eyes, nasal congestion, runny nose, itchy nose and sneezing.

Additional key features of FLONASE Sensimist include nasal allergy relief indicated for adults and children ages 2 and older and the fact that there is little or no drip.

Flonase Sensimist will be nationally available OTC in early 2017.